IMA Advisory Services’s BeOne Medicines Ltd ONC Stock Holding History

IMA Advisory Services’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.71K	Buy	6 +2	+50%	+$589	﹤0.01%	1132
2026 Q1	$1.19K	Sell	4 -1	-20%	-$324	﹤0.01%	751
2025 Q4	$1.52K	Buy	+5	New	+$1.64K	﹤0.01%	723

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

IMA Advisory Services's ONC Position: Q2 2026 in Review

IMA Advisory Services increased its BeOne Medicines Ltd (ONC) stake by 50% in Q2 2026, buying an estimated $589 and bringing the position to 6 shares worth $1.71K. The position accounts for ﹤0.01% of the portfolio, ranked #1132.

IMA Advisory Services first reported a position in ONC in Q4 2025 and has held it in 3 quarters since. 283 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

IMA Advisory Services held 6 shares of BeOne Medicines Ltd worth $1.71K as of Q2 2026.
IMA Advisory Services bought 2 BeOne Medicines Ltd shares in Q2 2026, an estimated $589.
BeOne Medicines Ltd made up ﹤0.01% of IMA Advisory Services's portfolio in Q2 2026, its #1132 holding.
IMA Advisory Services first reported a position in BeOne Medicines Ltd in Q4 2025 and has held it in 3 quarters since.
283 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on IMA Advisory Services's 13F filing for Q2 2026, filed 10 Aug 2026.